All Articles
No Single Pharma Model For Commercialization of Biomarkers (View from a Companion Diagnostics Company)

No Single Pharma Model For Commercialization of Biomarkers (View from a Companion Diagnostics Company)

12 October, 2012

Featured

Richard Kennedy of Almac Diagnostics and Queen's University, Belfast writes that in his experience there is no one route to market for biomarkers in the personalized medicine space. Each pharmaceutical and diagnostic company has its own preferred model and, by focusing on companion diagnostic assays that will be used for the registration of a drug, their approaches can be broadly summarized in three models.|Richard Kennedy of Almac Diagnostics and Queen's University, Belfast writes that in his experience there is no one route to market for biomarkers in the personalized medicine space. Each pharmaceutical and diagnostic company has its own preferred model and, by focusing on companion diagnostic assays that will be used for the registration of a drug, their approaches can be broadly summarized in three models.|Richard Kennedy of Almac Diagnostics and Queen's University, Belfast writes that in his experience there is no one route to market for biomarkers in the personalized medicine space. Each pharmaceutical and diagnostic company has its own preferred model and, by focusing on companion diagnostic assays that will be used for the registration of a drug, their approaches can be broadly summarized in three models.|Richard Kennedy of Almac Diagnostics and Queen's University, Belfast writes that in his experience there is no one route to market for biomarkers in the personalized medicine space. Each pharmaceutical and diagnostic company has its own preferred model and, by focusing on companion diagnostic assays that will be used for the registration of a drug, their approaches can be broadly summarized in three models.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny